Intellus Advisors’s Karyopharm Therapeutics KPTI Stock Holding History
Bought
Maintained
Sold
Other funds holding KPTI
ACA
Intellus Advisors's KPTI Position: Q3 2026 in Review
Intellus Advisors opened a new position in Karyopharm Therapeutics (KPTI) in Q3 2026: 38,232 shares worth $46.6K. The stake represents 0.01% of the portfolio and ranks #152 among its holdings.
92 funds tracked by Wall St. Rank hold KPTI as of Q3 2026.
- Intellus Advisors held 38,232 shares of Karyopharm Therapeutics worth $46.6K as of Q3 2026.
- Karyopharm Therapeutics was a new Intellus Advisors position in Q3 2026.
- Karyopharm Therapeutics made up 0.01% of Intellus Advisors's portfolio in Q3 2026, its #152 holding.
- 92 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2026.
Based on Intellus Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.